- Home
- SPRY vs IMNM Comparison
SPRY vs IMNM Comparison
Compare SPRY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- IMNM
- Stock Information
- Founded
- SPRY 2015
- IMNM 2006
- Country
- SPRY United States
- IMNM United States
- Employees
- SPRY N/A
- IMNM N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- SPRY Health Care
- IMNM Health Care
- Exchange
- SPRY Nasdaq
- IMNM Nasdaq
- Market Cap
- SPRY 1.1B
- IMNM 1.2B
- IPO Year
- SPRY N/A
- IMNM 2020
- Fundamental
- Price
- SPRY $9.59
- IMNM $18.67
- Analyst Decision
- SPRY Strong Buy
- IMNM Strong Buy
- Analyst Count
- SPRY 4
- IMNM 8
- Target Price
- SPRY $31.25
- IMNM $25.75
- AVG Volume (30 Days)
- SPRY 2.5M
- IMNM 1.4M
- Earning Date
- SPRY 11-10-2025
- IMNM 11-06-2025
- Dividend Yield
- SPRY N/A
- IMNM N/A
- EPS Growth
- SPRY N/A
- IMNM N/A
- EPS
- SPRY N/A
- IMNM N/A
- Revenue
- SPRY $142,772,000.00
- IMNM $9,679,000.00
- Revenue This Year
- SPRY N/A
- IMNM N/A
- Revenue Next Year
- SPRY $193.13
- IMNM $85.36
- P/E Ratio
- SPRY N/A
- IMNM N/A
- Revenue Growth
- SPRY 5459.66
- IMNM N/A
- 52 Week Low
- SPRY $6.66
- IMNM $5.15
- 52 Week High
- SPRY $18.90
- IMNM $19.16
- Technical
- Relative Strength Index (RSI)
- SPRY 57.78
- IMNM 62.73
- Support Level
- SPRY $6.66
- IMNM $17.96
- Resistance Level
- SPRY $7.40
- IMNM $19.16
- Average True Range (ATR)
- SPRY 0.80
- IMNM 1.21
- MACD
- SPRY 0.21
- IMNM 0.03
- Stochastic Oscillator
- SPRY 78.83
- IMNM 86.50
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.